Sara Zelinskas
8 Papers
1 Citations
Sara Zelinskas is an academic researcher. The author has contributed to research in topics: Gene & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
Himanshu Savardekar,Carter Allen,H. Jeon,Jianying Li,Dionisia Quiroga,E. Schwarz,Richard C Wu,Sara Zelinskas,Gabby Lapurga,Alexander Abreo,Andrew Stiff,Jami Shaffer,Bradley W. Blaser,Matthew Old,Robert Wesolowski,Gang Xin,Kari L Kendra,Dongjun Chung,William E Carson +18 more
TL;DR: Single-cell RNA sequencing analysis reveals that BTK inhibition with ibrutinib downregulates key genes and pathways in myeloid-derived suppressor cells from cancer patients, particularly in melanoma, enhancing antitumor activity of anti-PD-1 antibody treatments.
3
Distal Femoral Locking Plates for Tibiotalocalcaneal Fusions in the Charcot Ankle: A retrospective study
TL;DR: A small case series shows promise to the efficacy of distal femoral locking plates for tibiotalocalcaneal fusions in Charcot neuroarthropathy, with evidence of radiographic consolidation across the fusion sites.
Abstract 3764: Expression patterns of microRNAs and associated target genes in ulcerated primary cutaneous melanoma
E. Schwarz,Mallory J. DiVincenzo,Casey Ren,Zoe Barricklow,Maribelle Moufawad,Lianbo Yu,Paolo Fadda,Colin D Angell,Sara Zelinskas,Steven Sun,J. Harrison Howard,Catherine Chung,Craig L. Slingluff,Alejandro A. Gru,Kari Kendra,William E. Carson +15 more
TL;DR: Schwarz et al. as mentioned in this paper showed that a unique subset of miRNAs and mRNAs are differentially expressed in ulcerated melanoma when compared to non-ulcerated.
CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
Dionisia Quiroga,Ashley Pinette,Brooke Benner,E. Schwarz,Robert Wesolowski,Andrew Stiff,Sara Zelinskas,Erin Macrae,Maryam B. Lustberg,Ewa Mrozek,Bhuvaneswari Ramaswamy,William E. Carson +11 more
TL;DR: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination with Trastuzumab in Patients With Metastatic Breast Cancer as mentioned in this paper .
Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers.
Jessica Mezzanotte-Sharpe,Chih-Yuan Hsu,David Choi,Hollie Sheffield,Sara Zelinskas,Ekaterina Proskuriakova,M. Montalvo,J. Whisenant,Keaton Gaffney,M. S. Thompson,Kim Blenman,Karine Tawagi,Lynn Symonds,Cesar A. Santa-Maria,Nisha Unni,Dionisia Quiroga,Yu Shyr,Laura C Kennedy +17 more
TL;DR: This study reports on 415 TNBC patients treated with neoadjuvant chemo/immunotherapy, finding high-grade adverse events (88%) and hospitalization rates (26%), with obese patients at increased risk of hospitalization, and a lower pathologic complete response rate compared to previous studies.